- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Poor adherence to warfarin therapy significantly affects anticoagulation control
Patients who fail to adhere to warfarin therapy as prescribed are more likely to experience problems with anticoagulation control, according to the authors of the International Normalized Ratio Adherence and Genetics (IN-RANGE) study.
Key Points
Patients who fail to adhere to warfarin therapy as prescribed are more likely to experience problems with anticoagulation control, according to the authors of the International Normalized Ratio Adherence and Genetics (IN-RANGE) study published in the journal Archives of Internal Medicine.
"Adherence to long-term medication regimens, including cardiovascular therapies, is a major challenge facing patients and healthcare providers," the authors stated. "This is particularly true for narrow therapeutic index drugs such as warfarin."
In this prospective cohort study involving 3 anticoagulation clinics in Pennsylvania, 136 patients were treated with warfarin for various indications (with a goal international normalized ratio [INR] of 2–3). Adherence to anticoagulation therapy was monitored using electronic Medication Event Monitoring System (MEMS) medication bottle caps. After using multivariate logistic regression to adjust for factors that might affect a patient's response to warfarin, it was demonstrated that every 10% increase in missed pill-bottle-openings was associated with a 14% increase in the odds of under-anticoagulation (defined as INR <2; P<.001). The odds of under-anticoagulation were increased 100% for patients who missed >20% bottle openings (adjusted OR=2.10; 95% CI, 1.48–2.96).
"This study demonstrates that poor adherence is potentially a major source of poor anticoagulation control, even among patients being treated in specialized anticoagulation clinics where the importance of adherence is constantly emphasized," the authors stated.
It is estimated that poor patient adherence to medications is responsible for more than 5.3% of all hospital admissions at a cost of more than $8 billion.
SOURCE Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) study. Arch Intern Med. 2007;167:229–235.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
